Sylvester Comprehensive Cancer Center

  • 20240367 - Bialick Steven

  • Investigator:
    Steven Bialick
    RCname Email

    		Coordinator:

    IRB: 20240367

    		SDG: Bone and Soft Tissue (Sarcoma)
    Disease Site(s):

    Soft Tissue
    Sponsor: SARC

    Enrolling Sites:

    Aventura
    Coral Springs
    Deerfield
    Gables
    Hollywood
    Kendall
    Plantation
    Sylvester
    UMH
    Title:

    A Phase II Trial of bezuclastinib in combination with sunitinib in patients with GIST who progressed on sunitinib monotherapy
    Eligibility Criteria - NCT06208748 *This information has been extracted from " www.clinicaltrials.gov"

  • 20231142 - Jonczak Emily

  • Investigator:
    Emily Jonczak
    RCname Email

    		Coordinator:

    IRB: 20231142

    		SDG: Bone and Soft Tissue (Sarcoma)
    Disease Site(s):

    Soft Tissue
    Sponsor: POLARIS PHARMACEUTICALS

    Enrolling Sites:

    Coral Springs
    Deerfield
    Gables
    Hollywood
    Plantation
    Sylvester
    UMH
    Title:

    ADI-PEG 20 or Placebo Plus Gemcitabine and Docetaxel in Previously Treated Subjects with Leiomyosarcoma (ARGSARC): A Randomized, Double-Blind, Multi-Center Phase 3 Trial
    Eligibility Criteria - NCT05712694 *This information has been extracted from " www.clinicaltrials.gov"

  • 20240676 - Jonczak Emily

  • Investigator:
    Emily Jonczak
    RCname Email

    		Coordinator:

    IRB: 20240676

    		SDG: Bone and Soft Tissue (Sarcoma)
    Disease Site(s):

    Soft Tissue
    Sponsor: ECOG

    Enrolling Sites:

    Coral Springs
    Deerfield
    Gables
    Hollywood
    Kendall
    Plantation
    Sylvester
    UMH
    Title:

    A Randomized Phase III Trial of Doxorubicin + Pembrolizumab Versus Doxorubicin Alone for the Treatment of Undifferentiated Pleomorphic Sarcoma (UPS) and Related Poorly Differentiated Sarcomas
    Eligibility Criteria - NCT06422806 *This information has been extracted from " www.clinicaltrials.gov"

  • 20201368 - Trent Jonathan

  • Investigator:
    Jonathan Trent
    RCname Email

    		Coordinator:

    IRB: 20201368

    		SDG: Bone and Soft Tissue (Sarcoma)
    Disease Site(s):

    Multiple
    Sponsor: SCCC

    Enrolling Sites:

    Plantation
    Sylvester
    Title:

    ctDNA-Guided Sunitinib And Regorafenib Therapy for Gastrointestinal Stromal Tumor (GIST)
    Eligibility Criteria - NCT05366816 *This information has been extracted from " www.clinicaltrials.gov"

  • 20220946 - Trent Jonathan

  • Investigator:
    Jonathan Trent
    RCname Email

    		Coordinator:

    IRB: 20220946

    		SDG: Bone and Soft Tissue (Sarcoma)
    Disease Site(s):

    Bones and Joints
    Sponsor: ADVENCHEN LABORATORIES

    Enrolling Sites:

    Sylvester
    Title:

    An Open Label Post-Trial Access (PTA) of Catequentinib (AL3818, Anlotinib) Hydrochloride Mono or in Combination Therapies in Patients Who Have Completed an Advenchen Sponsored Oncology Study with AL3818 (A Compassionate Use Trial)
    Eligibility Criteria - NCT05612191 *This information has been extracted from " www.clinicaltrials.gov"

  • 20231413 - Trent Jonathan

  • Investigator:
    Jonathan Trent
    RCname Email

    		Coordinator:

    IRB: 20231413

    		SDG: Bone and Soft Tissue (Sarcoma)
    Disease Site(s):

    Bones and Joints
    Sponsor: Institut de Recherches Internationales Servier (I.R.I.S.)

    Enrolling Sites:

    Deerfield
    Plantation
    Sylvester
    UMH
    Title:

    A Phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib in participants =18 years of age with locally advanced or metastatic conventional chondrosarcoma with an IDH1 mutation, untreated or previously treated with 1 systemic treatment regimen (CHONQUER study)
    Eligibility Criteria - NCT06127407 *This information has been extracted from " www.clinicaltrials.gov"

  • 20231415 - Trent Jonathan

  • Investigator:
    Jonathan Trent
    RCname Email

    		Coordinator:

    IRB: 20231415

    		SDG: Bone and Soft Tissue (Sarcoma)
    Disease Site(s):

    Soft Tissue
    Sponsor: DECIPHERA

    Enrolling Sites:

    Deerfield
    Plantation
    Sylvester
    Title:

    An International, Phase 3, Randomized, Multicenter, Open-label Study of Ripretinib vs Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumor (GIST) with KIT Exon 11 and Co-occurring KIT Exons 17 and/or 18 Mutations Who Were Previously Treated with Imatinib (INSIGHT)
    Eligibility Criteria - NCT05734105 *This information has been extracted from " www.clinicaltrials.gov"